Acceptance and results of therapy with omalizumab in real world Kerala setting: reports from the ARTWORK study, Kerala, South India
| Autor: | Jolsana Augustine, Elda Kuriachen, Aparna S. Nirmal, Anju Sasi, Melcy Cleetus, Susan John, Divya Ramachandran, Rajesh Venkitakrishnan, Anand Vijay |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Opting out Exacerbation business.industry India Retrospective cohort study Omalizumab Guideline medicine.disease Patient preference Asthma Treatment Outcome Pediatrics Perinatology and Child Health Humans Immunology and Allergy Medicine Anti-Asthmatic Agents business Intensive care medicine Adverse effect Retrospective Studies medicine.drug |
| Zdroj: | Journal of Asthma. 59:1831-1838 |
| ISSN: | 1532-4303 0277-0903 |
| Popis: | OBJECTIVE Despite the availability of effective medications, only a minority of asthma patients achieve guideline defined asthma control. Treatment success depends on patient concurrence to the prescribed drug and adherence to treatment. It is therefore crucial to identify the patient preferences as well as attitudes towards asthma medications. Omalizumab is recommended as a preferred option in step 5 of asthma therapy. There have been few studies to address patient perspectives on omalizumab therapy in India. METHODS This was a retrospective study. Patients with inadequate asthma control were considered for the study. Systematic evaluation was done to identify and correct modifiable factors that can worsen asthma control. Patients with persisting poor asthma control who were deemed suitable to receive this agent were evaluated with their attitudes toward acceptance or refusal and the reasons for opting out were noted. The patients who received omalizumab were followed up to determine the results of treatment and duration of adherence to therapy. RESULTS Thirty-five patients out of 51 patients chose to avoid this drug. The reasons for opting out included erroneous perception of optimal asthma control, cost of therapy, and concern about adverse effects. Patients took omalizumab for a median duration of 6 months. Improved asthma control and decreased frequency of exacerbation was noted in all patients which persisted during the 6-month follow-up. CONCLUSIONS The majority of patients needing step 5 therapy opt out of omalizumab. Cost of drug, duration of therapy and erroneous perception of good asthma control account for refusing treatment. Omalizumab affords excellent clinical benefits to patients who receive it, and the benefits extend beyond the duration of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|